Replies to post #35510 on Cytodyn Inc (CYDY)

[finesand]

Black - good questions, yes.

DVAX borrowed a few $50M - $150M to build up sales and their other drug. At the brink to failure - financially.

Your new sales team also need to learn to play along properly, a new process. This takes time - which is costly in itself.

I expect Monotherapy HIV-1 and Cancer to be 'good enough' to have our door run into with offers (o8>
Similar like you that is.

But if the reward is not handing ~50% or more of gross revenues to BP just because they're kind enough to agree to sell a product that they've shouldered no risk in developing,

That is also my big question and it depends on the timeframe and how it is being financed.

IMHO it is better to let an experienced BP handle sales and get 'only' 25-40% royalties on _SALES_ than to build up a fresh new sales team and grow company 10x.
But of course, many have other opinions about that.
When DVAX started to go alone, the downfall began.
Other companies, years ago .. had a similar learning curve.
Hence I would prefer a fast solution after our FDA success.

We may have to agree to disagree on this one, and that's fine.

Yes, I agree. Most important we understand the question. Outcome may differ - I also have no crystal ball.